In vivo metabolism of norbormide in rats and mice

Environmental Toxicology and Pharmacology

Volumn 28, Issue 1, 2009, Pages 147-151

  Ravindran, Shanthinie ^a,b   Hopkins, Brian ^b   Bova, Sergio ^c   Tingle, Malcolm ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b LANDCARE RESEARCH   (New Zealand)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hydroxylation; In vivo; Metabolism; Norbormide; Species selectivity

Indexed keywords

NORBORMIDE; NORBORNENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; FEMALE; HYDROXYLATION; LETHALITY; LIVER LEVEL; LIVER METABOLISM; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; XENOBIOTIC METABOLISM;

CAVIA; MUS; RATTUS;

EID: 67349162689     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2009.03.013     Document Type: Article

References (17)

1. Bova S., Trevis L., Debetto P., Cima L., Furnari M., Luciani S., Padrini R., and Cargnelli G. Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature. Br. J. Pharmacol. 117 6 (1996) 1041-1046
2. Bova S., Trevisi L., Cima L., Luciani S., Golovina V., and Cargnelli G. Signalling mechanisms for the selective vasoconstrictor effect of norbormide on the rat small arteries. J. Pharmacol. Exp. Ther. 296 (2001) 458-463
3. Brimble M.A., Muir V.J., Hopkins B., and Bova S. Synthesis and evaluation of vasoconstrictor and vasorelaxant activity of norbormide isomers. ARKIVOC i (2004) 1-11
4. Cavalli M., Omiciuolo L., Cargnelli G., Cima L., Hopkins B., and Bova S. Distribution of the vasoconstrictor and vasorelaxant effects of norbormide along the vascular tree of the rat. Life Sci. 75 18 (2004) 2157-2165
5. Henderson R.F. Species differences in the metabolism of benzene. Environ. Health Perspect. 104 6 (1996) 1173-1175
6. Hucker H.B. Species differences in drug metabolism. Annu. Rev. Pharmacol. 10 (1970) 99-118
7. Mitchell J.R., Jollow D.J., Potter W.Z., Davis D.C., Gillette J.R., and Brodie B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187 (1973) 185-194
8. Poos G.I., Mohrbache R.J., Carson E.L., Paragamian V., Puma B.M., Rasmussen C.R., and Roszkowski A.P. Structure-activity studies with the selective toxicant norbormide. J. Med. Chem. 9 4 (1966) 537-540
9. Przyborowski T., and Hillar M. Investigations on the rat-killing properties of the compounds of the norbormide group (shoxin). Biuletyn Instytutu Medycyny Morskiej W Gda'nsku 19 3 (1968) 211-216
10. Ravindran S., Hopkins B., Bova S., Rennison D., Brimble M., and Tingle M.D. In vitro metabolism of norbormide in rat, mouse and guinea pig liver preparations. Environ. Toxicol. Pharmacol. 27 (2009) 144-148
11. Ricchelli F., Dabbeni-Sala F., Petronilli V., Bernardi P., Hopkins B., and Bova S. Species-specific modulation of the mitochondrial permeability transition by norbormide. Biochim. Biophys. Acta 1708 (2005) 178-186
12. Roszkowski A.P. The pharmacological properties of norbormide, a selective rat toxicant. J. Pharmacol. Exp. Ther. 149 2 (1965) 288-299
13. Roszkowski A.P., Poos G.I., and Mohrbacher R.J. Selective rat toxicant. Science 114 (1964) 253-261
14. Russell R.U. Norbormide-a rattus specific toxic agent. J. Forensic Sci. (1965) 80-83
15. Tingle M.D., Mahmud R., Maggs J.L., Pirmohamed M., and Park B.K. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J. Pharmacol. Exp. Ther. 283 2 (1997) 817-823
16. USFDA, CDER, CVM, 2001. Guidance for Industry: Bioanalytical Method Validation, pp. 1-20.
17. Zulian A., Petronilli V., Bova S., Dabbeni-Sala F., Cargnelli G., Cavalli M., Rennison D., Stäb J., Laita O., Lee D.J., Brimble M.A., Hopkins B., Bernardi P., and Ricchelli F. Assessing the molecular basis for rat-selective induction of the mitochondrial permeability transition by norbormide. Biochim. Biophys. Acta 1767 7 (2007) 980-988